Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific presentations featuring its FDA-authorized image-only AI model at the Radiological Society of North America (RSNA) 2025 Annual Meeting, Nov. 30 to Dec. 4 in Chicago. The studies highlight Clairity’s approach to estimating 5-year breast cancer risk from a single screening mammogram and demonstrate the model’s clinical accuracy, calibration, and utility across diverse global populations.

Oct. 6, 2025 — Hyperfine, Inc. has launched the Portable Ultra-Low-Field Scientific Exchange (PULSE), a subscription-based platform designed to empower a global community of clinical researchers and developers advancing access and innovation in portable MRI.

Hyperfine is the developer of the first FDA-cleared AI-powered portable MRI system for the brain the Swoop system

Oct. 3, 2025 — IceCure Medical Ltd., developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, recently announced that the U.S. Food and Drug Administration has granted marketing authorization to IceCure's De Novo application for the ProSense cryoablation system for the local treatment of breast cancer in patients ≥70 years of age with biologically low-risk tumors ≤1.5 cm in size and treated with adjuvant endocrine therapy, representing approximately 46,000 women annually in the U.S.

Oct. 3, 2025 — Gnosis for Her, a mobile breast health initiative redefining comfort and access in women's breast imaging, made its national debut this past weekend at Susan G. Komen's More Than Pink Walk in Newport Beach, Calif. More than 6,000 breast cancer survivors, loved ones, advocates and supporters had the opportunity to see the Mobile Care Unit up close, tour inside, and speak with the expert team behind the service. 

Early detection is key to breast cancer survival. But nearly half of all women in the U.S.

Sept. 25, 2025 — Siemens Healthineers has launched its first United States-based Experience Center at The Pearl, Advocate Health’s innovation district in Charlotte, North Carolina.

Sept. 28, 2025 — Leo Cancer Care has launched Grace, the company's upright photon therapy system. Grace is named after American computer scientist and U.S. Navy Rear Admiral Grace Hopper, who famously said, "The most dangerous phrase in language is 'But we've always done it this way.'" The name reflects Leo Cancer Care's mission to challenge the conventions of radiation therapy. The launch took place at ASTRO 2025 in San Francisco, California.

September 24, 2025—According to the American Journal of Roentgenology (AJR), MRI can reliably identify lateral meniscal oblique radial tears (LMORTs) — a biomechanically important tear pattern associated with anterior cruciate ligament (ACL) injury — using arthroscopy as the reference standard.

Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong prognostic information, treatments for prostate cancer patients can be personalized according to tumor evolution, significantly impacting their overall survival. This research was published online in The Journal of Nuclear Medicine.

Oct. 01, 2025 – Nuclidium AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering the company’s Kalios-program.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now